Brought to you by 
NuVasive buys Osiris's Osteocel business
May 2008
Executive Summary
Osiris Therapeutics (stem cell therapies for inflammatory, orthopedic, and cardiovascular indications) has sold NuVasive (minimally invasive devices for spine surgeries) its Osteocel biologics business, including a processing facility.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Includes Contract
- Full Acquisition
- Includes Earnout
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com